Home » Stocks » ARNA

Arena Pharmaceuticals, Inc. (ARNA)

Stock Price: $64.68 USD -0.15 (-0.23%)
Updated November 23, 4:00 PM EST - Market closed
After-hours: $64.60 -0.08 (-0.12%) Nov 23, 7:52 PM

Stock Price Chart

Key Info

Market Cap 3.76B
Revenue (ttm) 3.28M
Net Income (ttm) -370.88M
Shares Out 58.16M
EPS (ttm) -7.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 23
Last Price $64.68
Previous Close $64.83
Change ($) -0.15
Change (%) -0.23%
Day's Open 64.94
Day's Range 63.83 - 65.46
Day's Volume 530,148
52-Week Range 32.95 - 90.19

More Stats

Market Cap 3.76B
Enterprise Value 2.64B
Earnings Date (est) Mar 2, 2021
Ex-Dividend Date n/a
Shares Outstanding 58.16M
Float 57.95M
EPS (basic) -7.09
EPS (diluted) -7.04
FCF / Share -5.38
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.63M
Short Ratio 5.22
Short % of Float 6.26%
Beta 1.18
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1,145.57
PB Ratio 3.22
Revenue 3.28M
Operating Income -385.21M
Net Income -370.88M
Free Cash Flow -310.71M
Net Cash 1.12B
Net Cash / Share 19.28
Gross Margin 17,507.16%
Operating Margin -11,729.93%
Profit Margin -11,293.70%
FCF Margin -9,461.30%
ROA -19.13%
ROE -32.03%
ROIC -42.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (14)

Buy 14
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$94.79*
(46.55% upside)
Low
76.0
Current: $64.68
High
116.0
Target: 94.79
*Average 12-month price target from 14 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue80617.9721.3492.1613.4036.9781.3927.5912.7216.61
Revenue Growth4387.65%-15.78%-76.85%587.89%-63.76%-54.58%195.04%116.9%-23.44%-
Gross Profit80617.9721.3492.1613.4029.2175.2123.924.629.20
Operating Income483-145-91.97-5.26-104-105-22.94-57.11-82.80-96.36
Net Income398-29.40-91.41-22.52-108-60.51-19.44-85.48-109-125
Shares Outstanding49.7847.0432.9924.3124.0721.9721.8119.6513.9210.96
Earnings Per Share7.69-0.63-2.77-0.93-4.49-2.80-0.90-4.50-8.00-11.40
Operating Cash Flow569-132-66.64-61.48-98.11-10172.80-44.05-78.26-52.32
Capital Expenditures-4.82-0.690.680.141.11-8.86-9.10-1.75-0.59-4.16
Free Cash Flow564-133-65.97-61.34-97.00-11063.70-45.79-78.84-56.48
Cash & Equivalents74044624790.7115616322215657.63151
Total Debt49.4352.7161.7565.2768.2570.7472.7974.4690.47125
Net Cash / Debt69039318525.4587.9492.4714981.63-32.8425.76
Assets1,174687339169257276340261157266
Liabilities10380.65132129203229248163147186
Book Value1,07160620739.9053.5447.3591.8698.6410.5680.02
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Arena Pharmaceuticals, Inc.
Country United States
Employees 320
CEO Amit Dilip Munshi

Stock Information

Ticker Symbol ARNA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARNA
IPO Date July 28, 2000

Description

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, a Phase IIb/III clinical trial for Crohn's disease, and a Phase IIb clinical trial for atopic dermatitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; and APD418 that is in Phase I clinical trial for acute heart failure. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Company and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.